Marc Stapley

CEO Marc Stapley sells 138,051 VCYT shares at $50.12 via scheduled 10b5-1 plan; retains 440,494 shares post-sale

Marc Stapley, Chief Executive Officer of Veracyte, sold 138,051 shares (138.1K shares) for $6,919,585.49 on 2026-06-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, reducing his direct holdings from 578,545 to 440,494 shares. The sale represents a 23.9% reduction of pre-transaction holdings, executed at $50.12, near the 52-week high of $50.71, as the stock has gained 51.5% over the past 30 days and 47.5% over 90 days. The transaction is scheduled under a trading plan, so it reflects a pre-determined execution rather than a discretionary timing decision. Notably, Stapley's prior five sales at Veracyte have shown mixed results: three earlier 2025 sales posted negative 30-day and 90-day returns, while two March 2026 sales saw near-term declines (-9.3% and -11.1% at 30 days) followed by strong 90-day recoveries (+34.4% and +31.8%). The company's fundamentals remain solid with annual revenue growth of +16.0%, net income of $28,707,000.00, and a market cap of $3,984,844,791.18 ($4.0B), though the P/E of 45.40 reflects premium valuation. The CEO retains a substantial equity stake of 440,494 non-derivative shares post-transaction.

CEO Marc Stapley sold 45,523 shares for $1,637,594.15 under pre-arranged 10b5-1 plan (adopted 2025-11-24)

Marc Stapley, CEO of Veracyte, sold 45,523 shares across 2 separate transactions on 2026-03-04, generating $1,637,594.15 at a blended average price of $35.97. This sale reduces his holdings from 403,077 shares to 357,554 shares, a decline of 11.3%. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, meaning the sale was scheduled in advance rather than discretionary. As a routine scheduled disposition under a trading plan, this filing does not provide insight into current insider sentiment regarding the company's valuation or prospects.

Director Marc Stapley sold 15,000 shares for $1,915,576.23 under pre-arranged 10b5-1 plan

Marc Stapley, a director at GLAUKOS Corp (GKOS), executed 5 separate sales totaling 15,000 shares for $1,915,576.23 on 2026-01-22, reducing his holdings from 52,449 to 37,449 shares. The sales occurred at prices ranging from $126.07 to $129.78, with a blended average price of $127.71. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-06-04, meaning the sales were scheduled and not discretionary decisions. Director Stapley retains 37,449 shares post-transaction, maintaining meaningful equity exposure to the company.

CEO Marc Stapley sold 52,697 shares for $1,756,855.23 under pre-arranged 10b5-1 plan

Marc Stapley, Chief Executive Officer of Veracyte Inc., executed 3 separate sales totaling 52,697 shares for $1,756,855.23 on 2025-03-04 under a 10b5-1 trading plan adopted on 2024-09-13. The sales occurred at prices ranging from $32.82 to $34.37, with a blended average of $33.34. Post-transaction, Stapley retains 268,035 shares, representing a 16.4% reduction in his shareholding. Because this transaction was part of a pre-arranged scheduled trading plan rather than a discretionary decision, it does not signal directional conviction about the stock's near-term prospects—the sale was determined months in advance and executed mechanically on the scheduled date.